CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings
Beginning Balance (in shares) at Sep. 30, 2022		13,047
Beginning balance at Sep. 30, 2022	$ 92,060	$ 13	$ 91,057	$ 990
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance and fair value adjustment of common stock in business combination (in shares)		527
Issuance and fair value adjustment of common stock in business combination	6,539	$ 1	6,538
Expense related to director restricted stock units	359		359
Expense related to employee stock-based compensation	993		993
Exercise of stock options (in shares)		286
Exercise of stock options	287		287
Common stock surrendered for the exercise of stock options (in shares)		(67)
Common stock surrendered for the exercise of stock options	(650)		(650)
Net income	2,352			2,352
Ending Balance (in shares) at Mar. 31, 2023		13,793
Ending balance at Mar. 31, 2023	101,940	$ 14	98,584	3,342
Beginning Balance (in shares) at Dec. 31, 2022		13,757
Beginning balance at Dec. 31, 2022	100,509	$ 14	97,958	2,537
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance and fair value adjustment of common stock in business combination (in shares)		0
Issuance and fair value adjustment of common stock in business combination	(461)	$ 0	(461)
Expense related to director restricted stock units	179		179
Expense related to employee stock-based compensation	621		621
Exercise of stock options (in shares)		36
Exercise of stock options	287		287
Net income	805			805
Ending Balance (in shares) at Mar. 31, 2023		13,793
Ending balance at Mar. 31, 2023	$ 101,940	$ 14	98,584	3,342
Beginning Balance (in shares) at Sep. 30, 2023	13,950	13,950
Beginning balance at Sep. 30, 2023	$ 102,439	$ 14	99,974	2,451
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	259		259
Expense related to employee stock-based compensation	$ 1,314		1,314
Exercise of stock options (in shares)	535	535
Exercise of stock options	$ 261		261
Common stock surrendered for the exercise of stock options (in shares)		(255)
Common stock surrendered for the exercise of stock options	(1,486)		(1,486)
Net income	$ 3,963			3,963
Ending Balance (in shares) at Mar. 31, 2024	14,230	14,230
Ending balance at Mar. 31, 2024	$ 106,750	$ 14	100,322	6,414
Beginning Balance (in shares) at Dec. 31, 2023		14,105
Beginning balance at Dec. 31, 2023	104,802	$ 14	100,186	4,602
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Expense related to director restricted stock units	180		180
Expense related to employee stock-based compensation	774		774
Exercise of stock options (in shares)		315
Exercise of stock options	0		0
Common stock surrendered for the exercise of stock options (in shares)		(190)
Common stock surrendered for the exercise of stock options	(818)		(818)
Net income	$ 1,812			1,812
Ending Balance (in shares) at Mar. 31, 2024	14,230	14,230
Ending balance at Mar. 31, 2024	$ 106,750	$ 14	$ 100,322	$ 6,414